Interaction Checker

Interaksi Pasireotid

Pasireotid (Signifor, Signifor LAR) memiliki 136 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 0 mayor, 135 moderat, 1 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi moderat (135)

  • Alfuzosinpenyekat alfaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • AmiodaronantiaritmiaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Amitriptilinantidepresan trisiklikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Amlodipinpenghambat kanal kalsium dihidropiridinModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Amlodipin dan atorvastatinpenghambat kanal kalsium dihidropiridinModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Amlodipin dan benazeprilpenghambat kanal kalsium dihidropiridinModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Amlodipin dan olmesartanpenghambat kanal kalsium dihidropiridinModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Amlodipin dan valsartanpenghambat kanal kalsium dihidropiridinModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Anagrelidobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Arsen trioksidaobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Asebutololpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • AsenapinantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Atenololpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Atenolol dan klortalidonpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Azelastin dan flutikasonantihistaminModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Azitromisinantibiotik makrolidaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • BeklometasonkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Betaksololpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • BetametasonkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Bisoprololpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Bisoprolol dan hidroklorotiazidpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Brimonidin dan timololagonis alfa-adrenergikModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Bromokriptinagonis dopaminModerat

    Bromocriptine: Consider bromocriptine dose reduction. (label Pasireotid, Interaksi obat)

  • BudesonidkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • DeflazakortkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • DeksametasonkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Dekstrometorfan dan kuinidinobat serotonergikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • DesonidkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Deutetrabenazinpenghambat VMAT2Moderat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • DisopiramidantiaritmiaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • DofetilidantiaritmiaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Dorzolamid dan timololpenghambat karbonat anhidraseModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • DronedaronantiaritmiaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Droperidolantagonis dopaminModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Eritromisinantibiotik makrolidaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • EsitalopramSSRIModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Esmololpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Felodipinpenghambat kanal kalsium dihidropiridinModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • FingolimodimunosupresanModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • FlekainidantiaritmiaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • FludrokortisonkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Flukonazolantijamur azolModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • FlunisolidkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • FluoksetinSSRIModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • FluosinonidkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • FlutikasonkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Granisetronobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • HalobetasolkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • HaloperidolantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • HidrokortisonkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Hidroksiklorokuinobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • HidroksizinantihistaminModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • IbutilidantiaritmiaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • IloperidonantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Isradipinpenghambat kanal kalsium dihidropiridinModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Karvedilolpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Ketokonazolantijamur azolModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Klaritromisinantibiotik makrolidaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • KlobetasolkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • KlorokuinantimalariaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • KlorpromazinantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • KlozapinantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • KuetiapinantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • KuinidinantiaritmiaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • KuininantimalariaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Labetalolpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • LevofloksasinfluorokuinolonModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Levotiroksinhormon tiroidModerat

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (label Pasireotid, Peringatan dan perhatian)

  • Levotiroksin dan liotironinhormon tiroidModerat

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (label Pasireotid, Peringatan dan perhatian)

  • Liotironinhormon tiroidModerat

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (label Pasireotid, Peringatan dan perhatian)

  • Loperamidobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • MetadonopioidModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • MetilprednisolonkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Metoprololpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Metoprolol dan hidroklorotiazidpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • MoksifloksasinfluorokuinolonModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • MometasonkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Nadololpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Nebivololpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Nifedipinpenghambat kanal kalsium dihidropiridinModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Nikardipinpenghambat kanal kalsium dihidropiridinModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Nilotinibobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Nimodipinpenghambat kanal kalsium dihidropiridinModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • OfloksasinfluorokuinolonModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Olanzapin dan fluoksetinantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Olopatadin dan mometasonantihistaminModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Ondansetronobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • PaliperidonantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Pentamidinobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • PimavanserinantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • PimozidantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Pindololpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Pitolisantobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Posakonazolantijamur azolModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • PrednisolonkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • PrednisonkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • ProkainamidantiaritmiaModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • PrometazinantihistaminModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Prometazin dan dekstrometorfanantihistaminModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Prometazin dan kodeinopioidModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Propiltiourasilobat antitiroidModerat

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (label Pasireotid, Peringatan dan perhatian)

  • Propranololpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Ranolazinobat yang memperpanjang interval QTModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • RisperidonantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • SiklesonidkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • SiklosporinimunosupresanModerat

    Cyclosporine: Consider additional monitoring. (label Pasireotid, Interaksi obat)

  • SiprofloksasinfluorokuinolonModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • SitalopramSSRIModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • SolifenasinantikolinergikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Sotalolpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • TakrolimusimunosupresanModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Tamoksifenmodulator reseptor estrogen selektifModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Telmisartan dan amlodipinpenghambat reseptor angiotensin II (ARB)Moderat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Teriparatidhormon tiroidModerat

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (label Pasireotid, Peringatan dan perhatian)

  • Tetrabenazinpenghambat VMAT2Moderat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Tiamazolobat antitiroidModerat

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (label Pasireotid, Peringatan dan perhatian)

  • Timololpenyekat betaModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • TioridazinantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • TolterodinantikolinergikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Toremifenmodulator reseptor estrogen selektifModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • TramadolopioidModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Tramadol dan parasetamolopioidModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • TrazodonantidepresanModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • TriamsinolonkortikosteroidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Valbenazinpenghambat VMAT2Moderat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Vardenafilpenghambat PDE5Moderat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • VenlafaksinSNRIModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumModerat

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

  • Vorikonazolantijamur azolModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • ZiprasidonantipsikotikModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

Penyebutan minor (1)

  • AlkoholAlkoholMinor

    In some reported post-marketing cases of ketoacidosis in patients taking SIGNIFOR LAR, factors predisposing to ketoacidosis such as acute illness, infection, pancreatic disorders (e.g., pancreatic malignancy or pancreatic surgery), and alcohol abuse were present. (label Pasireotid, Peringatan dan perhatian)

Periksa Pasireotid terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.